Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s … Continue reading →

Genprex (NASDAQ: GNPX) is at the forefront of pioneering cancer treatments, and it’s making waves with remarkable advancements in lung cancer therapy. The company will be sharing compelling clinical and preclinical data at the prestigious 2023 AACR-NCI-EORTC International Conference on … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced its entry into an exclusive license agreement related to a particular gene therapy for both type 1 and type … Continue reading →

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company recently announced that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company’s pioneering gene therapies for cancer and … Continue reading →

Clinical-stage cancer and diabetes gene therapy developer Genprex (NASDAQ: GNPX) continues to expand its intellectual property portfolio for the company’s diabetes gene therapy program, recently announcing that it has entered into an exclusive license agreement related to a particular gene … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage company developing life-changing gene therapies for patients with cancer and diabetes, recently celebrated an important milestone: the award of an orphan drug designation. The company announced August 10 that the United States Food and Drug … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to … Continue reading →

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to the company’s lead … Continue reading →